OrbiMed Raises $4.3 Billion across private investment funds including OrbiMed Private Investments IX, OrbiMed Asia Partners V and OrbiMed Royalty & Credit Opportunities IV.
Consistent with their predecessors, these new funds enable OrbiMed to invest globally, from seed stage for start-ups incubated by OrbiMed through growth capital opportunities.
OrbiMed works closely with its portfolio companies to provide tailored financing solutions, which can include equity, credit and royalty-based financing.
OrbiMed focuses on innovative and growth-oriented opportunities across healthcare sub-sectors, including biopharmaceuticals, medical devices, diagnostics and technologyenabled healthcare services.
OrbiMed is led by its 21 partners, with a growing team exceeding 130 professionals that contribute diverse, complementary skills across company incubation, strategy, operations and finance.
The firm’s professionals are based in a dozen global locations across key healthcare markets in North America, Europe and Asia. Investors in these new funds include a broad range of medical institutions, university endowments, foundations, pension funds, sovereign wealth funds and family offices.
Carter Neild, a Managing Partner of OrbiMed said, “OrbiMed is deeply appreciative of the continued support we’ve received from many long-standing partners who’ve invested in these funds, We will endeavor to meet our partners’ high expectations in the coming years.”
OrbiMed is a leading healthcare investment firm with more than $17 billion in assets under
management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds and royalty/credit funds.
OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies.